Research programme: neurodegenerative disease therapeutics - VECT-HORUS/Sanofi
Alternative Names: Peptide vectors - VECT-HORUS; Peptide-vector-antibody conjugatesLatest Information Update: 28 Feb 2019
At a glance
- Originator Sanofi
- Developer Sanofi; VECT-HORUS
- Class Antibodies; Drug conjugates; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Neurodegenerative-disorders in France (Parenteral)
- 19 Jan 2015 Sanofi in-licenses VECT-HORUS’s proprietary technology for peptide-vectors VECT-HORUS
- 19 Jan 2015 Early research in Neurodegenerative disorders in France (Parenteral)